Evaluation of Safe Use of SECURIDRAP® SELFIA®
Launched by GROUPE MULLIEZ-FLORY · Aug 18, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety of a special type of bedding called SECURIDRAP® SELFIA®, which is designed for patients who may experience confusion, cognitive difficulties, or behavioral issues. The trial is taking place in nine medical facilities in France and aims to ensure that this updated version of the bedding is safe for use. Researchers will closely monitor participants for any unwanted side effects while using the bedding.
To be eligible for the trial, participants must be at least 18 years old and have a doctor’s prescription for the SECURIDRAP® SELFIA®. They should also have some level of disorientation or cognitive impairment, be at risk of falling from bed, and be under guardianship if needed. Participants will need to provide their agreement to take part in the study. Throughout the trial, participants can expect to be closely observed for their safety and comfort while using the bedding. It's important to note that certain individuals, like those with severe agitation or who are currently involved in other clinical studies, cannot participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient at least 18 years old
- • Patient having a medical prescription for SÉCURIDRAP® SELFIA®
- • Patient in phase or state of disorientation
- • Patient with nocturnal behavior disordre
- • Patient with major cognitive impairment
- • Patient at risk of falling into bed
- • Patient subject to guardianship or curatorship
- • Patient beneficiary or affiliated to a social security scheme
- • Patient who has given their participation agreement aand informed consent
- Exclusion Criteria:
- • Patient and/or guardianship or curatorship refusing to agree to participate in the clinical investigation
- • Patient in psychiatry
- • Patient with severe agitation
- • Patient who will be agitated once installed in the SÉCURIDRAP® SELFIA®
- • Patient with intolerance to the medical device
- • Patient able to extract himself from SÉCURIDRAP® SELFIA®
- • Patient able to unlock the bed rails by himself
- • Patient without social coverage or not benefiting from it through a third party
- • Patient minor, pregnant woman, persons deprived of their liberty
- • Patient who participating or having participated in another clinical investigation, drug or medical device in the 30 days preceding inclusion
About Groupe Mulliez Flory
Groupe Mulliez-Flory is a distinguished clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on improving patient outcomes, the organization collaborates with leading medical professionals and institutions to conduct rigorous clinical trials across various therapeutic areas. Committed to ethical practices and regulatory compliance, Groupe Mulliez-Flory prioritizes patient safety and data integrity while striving to bring novel therapies to market. Their expertise and dedication position them as a key player in the clinical research landscape, fostering breakthroughs that enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rennes, , France
Lille, , France
Lyon, , France
Lille, Nord, France
Bailleul, , France
Bully Les Mines, , France
Hazebrouck, , France
Le Quesnoy, , France
Limoux, , France
Roubaix, , France
Saint Jean Delnous, , France
Patients applied
Trial Officials
François Pr PUISIEUX
Principal Investigator
CHU Lille
Aline Dr CORVOL
Principal Investigator
CHU Rennes
Sabine Dr AHMINE
Principal Investigator
Hospices Civils de Lyon
Thierry Dr LECRIQUE
Principal Investigator
CSSR La Clauze
Brigitte Dr GERS
Principal Investigator
USSAP- ASM LIMOUX
Marguerite Dr REY
Principal Investigator
USSAP- ASM LIMOUX
Valérie Dr WIEL
Principal Investigator
EHPAD l'Aquarelle
Brigitte Dr TILMONT
Principal Investigator
CMMF de Bailleul
Eddy Dr BAHEU
Principal Investigator
CH Hazebrouck
Denis Dr LEFEBVRE
Principal Investigator
CH Le Quesnoy
Philippe Dr VEAU
Principal Investigator
CSSR La Clauze
Pearlide Dr Kizonzolo-de-Bello
Principal Investigator
CHG Roubaix
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials